Resonance Health patent granted
Thursday, 13 October, 2005
Perth based Resonance Health (ASX:RHT) has been granted its first European patent.
The patent protects the core invention underlying the FerriScan test for the non-invasive measurement of liver iron concentration. It is the European equivalent to a US patent granted in 2003 which is also being prosecuted in several other jurisdictions.
The company is also prosecuting a second patent family to expand the company's technology platform.
The intellectual property assets relating to the FerriScan test are fully owned by Resonance Health, following its acquisition of Inner Vision Biometrics in May 2005.
The University of Sydney formalises cervical cancer elimination partnership
The success of a cervical cancer elimination program has led to the signing of a memorandum of...
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
